Liming Jin

Dr. Liming Jin

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
MCMeiling Chen
Meiling Chen
YYYihang Yu
Yihang Yu
TMTao Mi
Tao Mi
QGQitong Guo
Qitong Guo
BXBin Xiang
Bin Xiang
GWGuanghui Wei
Guanghui Wei
Renal fibrosis is a common pathological feature of various kidney diseases, leading to irreversible renal failure and end-stage renal disease. However, there are still no effective treatments to reverse renal fibrosis. This study aimed to explore the potential mechanism of a targeted drug for fibrosis. Here, unilateral ureteral obstruction (UUO)-treated mice and a TGF-β1-treated human renal tubular epithelial cell line (HK-2 cells) were used as models of renal fibrosis. Based on the changes of mRNA in UUO kidneys detected by transcriptome sequencing, MK-2206, an Akt inhibitor, was predicted as a potential drug to alleviate renal fibrosis through bioinformatics. We dissolved UUO mice with MK-2206 by gastric gavage and cultured TGF-β-induced HK-2 cells with MK-2206. Histopathological examinations were performed after MK-2206 intervention, and the degree of renal fibrosis, as well as the expression of Akt/mTOR pathway-related proteins, were evaluated by immunohistochemical staining, immunofluorescence staining, and Western blot. The results showed that MK-2206 significantly improved the pathological structure of the kidney. Furthermore, MK-2206 intervention effectively inhibited UUO- and TGF-β1-induced epithelial-mesenchymal transition, fibroblast activation, and extracellular matrix deposition. Mechanistically, MK-2206 treatment attenuated the activation of the Akt/mTOR signaling pathway. Taken together, our study revealed for the first time that MK-2206 is a promising drug for the improvement of renal fibrosis.

20 September 2023 in Stem Cells International
Verified
Journal Article
Open access
PDF file
HLHongxu Lu
Hongxu Lu
ZZzhaoxia zhang
zhaoxia zhang
ZWZhaoying Wang
Zhaoying Wang
JWJinkui Wang
Jinkui Wang
TMTao Mi
Tao Mi
DHdawei he
dawei he
Background. Long-term extensive use of glucocorticoids will lead to hormonal necrosis of the femoral head, and osteoblasts play an important role in the prevention of osteonecrosis. However, there is no complete cure for necrosis of the femoral head. Mesenchymal stem cell- (MSCs-) derived exosomes are widely used for the repair of various tissue lesions. Therefore, the aim of this study was to investigate the mechanism of dexamethasone- (DEX-) induced osteoblast apoptosis and the therapeutic effect of human umbilical cord MSC- (hucMSC-) derived exosome mimetic vesicles (EMVs) on osteoblast-induced apoptosis by DEX. Methods. The viability and apoptosis of primary MC3T3-E1 cells were determined by the Cell Counting Kit-8 (CCK-8), FITC-Annexin V/PI staining and immunoblot. The intracellular levels of reactive oxygen species (ROS) after DEX treatment were measured by 2, 7 -dichlorodihydrofluorescein diacetate (DCFH-DA) staining. In this study, hucMSC-EMVs and N-acetyl-l-cysteine (NAC) were used as therapeutic measures. The expression of B-cell lymphoma 2-associated X, Bcl 2, HO-1, and nuclear factor erythroid-derived 2-like 2 and MAPK- signaling pathway in osteogenic cell MC3T3-E1 cells treated with Dex was analyzed by the immunoblotting. Results. DEX significantly induced osteoblasts MC3T3-E1 apoptosis and ROS accumulation. MAPK-signaling pathway was activated in MC3T3-E1 after DEX treatment. hucMSC-EMVs intervention significantly downregulated DEX-induced MAPK-signaling pathway activation and ROS accumulation. In addition, hucMSC-EMVs can reduce the apoptosis levels in osteoblast MC3T3-E1 cells induced by DEX. Conclusions. Our study confirmed that hucMSC-EMVs regulates MAPK-signaling pathway and ROS levels to inhibit DEX-induced osteoblast apoptosis.

26 March 2019 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
GWGuifen Wei
Guifen Wei
YYYiting Yuan
Yiting Yuan
XHXinzhong He
Xinzhong He
LJLiming Jin
Liming Jin
DJDi Jin
Di Jin
The aim of the present study was to evaluate the expression and specific role of microRNA (miR)‑142‑5p in the progression of intrahepatic cholangiocarcinoma (ICC). Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate miR‑142‑5p expression in patients with ICC and healthy control subjects. The results revealed that plasma miR‑142‑5p was significantly increased in patients with ICC compared with the control group. Furthermore, miR‑142‑5p was also increased in ICC tissues compared with adjacent non‑neoplastic tissues. Compared with patients with Ta‑T1 stage ICC, miR‑142‑5p was significantly elevated in patients with ICC ≥T2 stage. Patients with ICC at G3 stage had much higher plasma miR‑142‑5p levels compared with those at G1/2 stage. Receiver operating characteristic analysis indicated that miR‑142‑5p could be used as a biomarker to differentiate patients with ICC from healthy controls. Kaplan‑Meier analysis demonstrated that plasma miR‑142‑5p was negatively correlated with survival in patients with ICC. A dual luciferase reporter assay indicated that miR‑142‑5p significantly suppressed the relative luciferase activity of pmirGLO‑PTEN‑3' untranslated region compared with the control group. In summary, the results of the present study provide novel data indicating that plasma miR‑142‑5p is significantly upregulated in patients with ICC. miR‑142‑5p may therefore have potential as a biomarker for screening patients with ICC from healthy controls.

1 February 2022 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
LJLi-Ming Jin
Li-Ming Jin
YLYuan-Xing Liu
Yuan-Xing Liu
JCJian Cheng
Jian Cheng
LZLin Zhou
Lin Zhou
HXHaiyang Xie
Haiyang Xie
SZShusen Zheng
Shusen Zheng

22 June 2026 in Children
Verified
Journal Article
Open access
PDF file
HLHuazhang Liu
Huazhang Liu
MPMinghui Pan
Minghui Pan
LJLiming Jin
Liming Jin
GCGuangjie Chen
Guangjie Chen
CTChang Tao
Chang Tao
XYXiang Yan
Xiang Yan
Objective: The aim of this study was to evaluate the safety and efficacy of robot-assisted laparoscopic ureteroureterostomy (RALUU) and laparoscopic ureteroureterostomy (LUU) for duplicated kidney malformations in infants. Methods: This retrospective comparative cohort included infants with duplicated kidney malformations who underwent RALUU or LUU between May 2021 and April 2025. Perioperative variables assessed included operative duration, blood loss, oral feeding time, FLACC pain score, hospital stay, and complications. Follow-up outcomes included changes in anteroposterior pelvic diameter (APD), ureteral diameter (UD), and renal function (RF) of the affected upper moiety, assessed using renal ultrasonography and radionuclide imaging, with preoperative measurements serving as the baseline reference. The minimum follow-up duration was 12 months. Surgical success was determined based on fulfillment of all three criteria: resolution or alleviation of clinical symptoms, a reduction in APD and UD, and preserved or improved upper-moiety renal function compared with baseline. Results: The final cohort consisted of 52 infants (RALUU, n = 28; LUU, n = 24). Demographic and clinical profiles were comparable between groups. RALUU was associated with a shorter operative duration than LUU (139.6 ± 16.6 vs. 151.8 ± 21.6 min, p = 0.029). Estimated blood loss, time to oral feeding, FLACC pain score, and hospital stay were comparable. Postoperative complications were observed in 2 RALUU patients and 3 LUU patients. One patient in the LUU group developed urine leakage, which was managed conservatively. Postoperative urinary tract infection occurred in 2 patients in each group. No patient required secondary surgery. At a mean follow-up of 26.8 ± 10.4 and 28.1 ± 11.7 months in the RALUU and LUU groups, both groups showed significant reductions in APD and UD, with preserved RF and a modest postoperative increase. Conclusions: Both RALUU and LUU were safe and effective for duplicated kidney malformations in infants. RALUU was associated with a shorter operative time, while postoperative recovery, complication rates, and follow-up outcomes were comparable.

1 October 2019 in Chinese Journal of Traumatology
Verified
Journal Article
Open access
HHHaijun Huang
Haijun Huang
SLShu Lei
Shu Lei
LYLin Yang
Lin Yang
LJLi-Ming Jin
Li-Ming Jin
Systemic air embolism is a rare but potentially fatal complication related to many factors. The purpose of this article is to alert clinicians once patients occurs an abnormal neurological and cardiovascular status, following minor traumatic treatment, air embolism should be considered. A 20-year-old man who presented with fungal pneumonia with lung cavities formation was admitted to an intensive care unit (ICU) and received positive airway pressure ventilation. Four days later, the fungal pneumonia was improved, but the patient's blood pressure and arterial oxygen saturation deteriorated, so computed tomography (CT) scans were preformed to reevaluate him. The scans detected air embolism in the left atrium and ventricle, ascending aorta, aortic arch and its branches (right brachiocephalic, bilateral common carotid and right subclavian arteries), descending aorta and right coronary artery. A CT scan of the abdomen revealed air in the spleen, cauda pancreatic, superior mesenteric artery and right external iliac artery. The patient died two days later from multiple organ dysfunction. We suggest that vascular air embolism should be considered under mechanical ventilation when patients' neurologic and cardiovascular status deteriorates, and hyperbaric oxygen therapy should be conducted immediately.